In silico screening and preclinical validation identify bavisant as a therapeutic candidate for multiple sclerosis.

Gacem N, Bezukladova S, Windener F, Karam T, Ottoboni L, Brambilla E, Ruffini F, Soman K, Garcia-Diaz B, Levy MJF, Cui QL, Formato A, Deboux C, Chazot J, Panic R, Albrecht S, Yilmaz EN, González RG, Eberini I, Olla S, Bresciani A, Goebels N, Zipp F, Agresti C, Antel J, Evercooren AB, Kuhlmann T, Baranzini SE, Panina-Bordignon P, Nait-Oumesmar B, Martino G. In silico screening and preclinical validation identify bavisant as a therapeutic candidate for multiple sclerosis. Sci Transl Med. 2026 Jan 21; 18(833):eads0633.